Linklaters has advised Theramex (a portfolio company of Carlyle and PAI Partners) on Theramex’s proposed acquisition of certain rights and assets relating to the menopause therapy drugs Femoston and Duphaston from Viatris, Inc., a NASDAQ-listed pharmaceutical company.
Theramex is a global speciality pharmaceutical company, solely committed to women’s health, operating in 80+ countries, with 500+ employees, 20+ products and serving 6m+ patients. The asset purchase will broaden Theramex’s product portfolio, which currently focuses on contraceptives, menopause therapies, osteoporosis products and fertility treatments.
Linklaters previously advised PAI Partners and Carlyle on the acquisition of Theramex from CVC Capital Partners in 2022, and has continued to support the business since.
Closing is subject to customary closing conditions including antitrust and foreign direct investment approvals and receipt of certain required consents.
The cross-jurisdictional team, combining multi-practice expertise and deep Healthcare and Life Sciences Sector experience, was led by Corporate partners Daniel Law and Alex Woodward, alongside managing associate Alex Selig, and associates Kaiya Kim-Saville, Asim Ayub, Tibi Sandu (all London) and Catherine Yuen (New York). Managing associate James Marlow (London) supported on ESG matters. The Commercial (Carve-Out) team was led by partner Marly Didizian, supported by associates Danny Greenland and Rachel Varnam (all London) and the IP team was led by partner Yohan Liyanage, supported by managing associate Stephanie Farrington, and associate Olivia Williams (all London).
Partners Neil Hoolihan (Brussels) and Jonathan Ford (London), managing associates Juliane Guderian (London) and Sebastian Plötz (Düsseldorf), advised on Antitrust matters.
Partner Jamie Coomber and associate Rohesia Vince (both London) led on Tax matters.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
